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Summary
Objective: Bone morphogenic protein (BMP) activities are controlled in part by antagonists. In human osteoarthritic (OA) cartilage, the BMP
antagonists follistatin and gremlin are increased but differentially regulated. Using the OA dog model, we determined if these BMP antagonists
were produced at different stages during the disease process by comparing their in situ temporal and spatial distribution.
Methods: Dogs were sacriﬁced at 4, 8, 10 and 12 weeks after surgery; normal dogs served as control. Cartilage was removed, differentiating
ﬁbrillated and non-ﬁbrillated areas. Immunohistochemistry and morphometric analyses were performed for follistatin, gremlin, BMP-2/4 and
IL-1b. Growth factor-induced gremlin expression was assessed in dog chondrocytes.
Results: Follistatin and gremlin production were very low in normal cartilage. Gremlin was signiﬁcantly up-regulated in both non-ﬁbrillated and
ﬁbrillated areas at 4 weeks, and only slightly increased with disease progression. Follistatin showed a time-dependent increased level in the
non-ﬁbrillated areas with signiﬁcance reached at 8e12 weeks; in the ﬁbrillated areas signiﬁcant high levels were seen as early as 4 weeks. In
the whole cartilage, follistatin and IL-1b temporal production showed similar patterns; this was also true for gremlin and BMP-2/4, though BMP-
2/4 production was already high in the normal dogs. Interestingly, data revealed that basic ﬁbroblast growth factor (bFGF) could be another
factor increasing gremlin expression early in the disease process. Comparison between superﬁcial and deep zones revealed similar patterns
for follistatin and IL-1b in the superﬁcial zone only; gremlin and BMP-2/4 had similar patterns in both zones.
Conclusion: Data show, for the ﬁrst time, different spatial and temporal production of gremlin and follistatin in cartilage during OA progression.
These ﬁndings may reﬂect different roles for each antagonist in this disease.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a degenerative disease of the articular
joints, characterizedbycartilagedegradation.Thebreakdown
of the cartilage matrix leads to the development of ﬁbrillation
and ﬁssures, the appearance of gross ulcerations, and full-
thickness loss. Alterations in the collagennetwork andproteo-
glycans are observed early during the disease process1,2.
Among the factors up-regulated in human OA are the
bone morphogenic proteins (BMPs) and some of their an-
tagonists3e6. BMPs belong to the transforming growth fac-
tor (TGF)-ß super-family of secreted signaling molecules7,8.
They play important roles during embryogenesis, and pro-
mote the formation of cartilage and bone. They also con-
tribute to the tissue homeostasis of adult cartilage by
promoting the production of some cartilage macromole-
cules. Several BMPs are present in the adult human car-
tilage9 and some are found elevated during OA. For
example, BMP-2/4 was shown to be increased in OA car-
tilage and present in osteophytes6. BMP-6 and BMP-7
appear to be present at similar levels in both normal*Address correspondence and reprint requests to: Dr Johanne
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263and OA adult human cartilage10e12. BMP-13 (cartilage de-
rived morphogenic protein (CDMP)-2, growth and differen-
tiation factor (GDF)-6) and BMP-14 (CDMP-1, GDF-5)
were also found in both normal and OA adult cartilage11.
Despite increased BMP levels in the OA cartilage, overall
anabolic activities are decreased with disease progres-
sion, suggesting the presence of some factor(s) interfer-
ing with their activity.
BMP activities are controlled in part by speciﬁc antago-
nists13,14, which prevent BMP interaction with their speciﬁc
receptors. Many BMP antagonists have been identiﬁed and
they differ in their speciﬁcity and afﬁnity for the BMPs. For
example, gremlin binds BMP-2, -4 and -7 with similar afﬁn-
ity15,16, whereas follistatin also binds these BMPs, but with
a higher afﬁnity for BMP-717,18.
The levels at which BMP antagonists are expressed in
pathological tissues may lead to decreased BMP anabolic
activity, consequently affecting tissue repair and remodel-
ing. We previously reported the involvement of three BMP
antagonists, follistatin, gremlin and chordin, in human
OA3,4. From these previous studies, we hypothesized that
follistatin and gremlin might be produced in the cartilage
at different stages during the OA process.
It is not possible to monitor the early stages of primary hu-
man OA, not only because of the slow course of the degen-
erative process, but also because of ethical considerations
that preclude taking biopsies at different stages of the dis-
ease. However, the use of animal models allows for such
264 G. Tardif et al.: BMP antagonists in early osteoarthritistime-oriented studies. One of the well-characterized types
of surgically induced OA models is the sectioning of the an-
terior cruciate ligament (ACL) in dogs, as the pathological
structural changes seen in this model reproduce those of
human OA. These changes include cartilage destruction,
synovial inﬂammation, subchondral bone alterations, and
the presence of osteophytes19e22. In this model, the earliest
time point reported for site-speciﬁc gene expression is 2
weeks post-surgery, with no evidence of OA-related
changes in gross histologic (cell morphology, density and
distribution and matrix architecture and composition) or bio-
chemical (proteoglycan and collagen levels) assess-
ments23. However, noticeable changes are detected by 4
weeks and major cartilage lesions occur within 12 weeks
post-surgery20,24,25. In addition, the OA dog model also
shows parameters indicative of the involvement of pro-
inﬂammatory and catabolic factors similar to those seen in
human OA at the clinical stage of the disease22,26. There-
fore, because this model displays the characteristics of
human OA, it is suitable for the study of OA progress.
The aim of this study was to investigate the production of
the two BMP antagonists, follistatin and gremlin, using the
experimental OA dog model, to examine their temporal
and spatial changes in the cartilage, and to correlate their
levels with those of anabolic (BMP-2/4) and catabolic
(IL-1b) factors involved in OA cartilage. To this end, immu-
nohistochemistry combined with morphometric analysis
was used as it is the most appropriate methodology to
investigate the production of these factors at speciﬁc loca-
tions and to follow their presence throughout the evolution
of the disease.Materials and methodsANIMALSTwenty-four adult crossbred dogs (2e3 years of age, 20e25 kg each)
were used. OA was induced in 17 dogs by surgically sectioning the ACL
of the right knee through a stab wound25. Prior to surgery, the animals
were anesthetized intravenously with pentobarbital sodium (25 mg/kg) and
intubated. Following surgery, the dogs were kept in animal care facilities
for 1 week, and were then sent to a housing farm. Seven non-operated (nor-
mal) animals were used as controls. Dogs were housed in a large pen where
they could exercise ad libitum. All dogs were sacriﬁced by intravenous injec-
tion. Operated dogs were sacriﬁced 4 weeks (n¼ 4), 8 weeks (n¼ 4), 10
weeks (n¼ 5), or 12 weeks (n¼ 4) after surgery. This study was approved
by the Institutional Ethics Committee.SPECIMEN SELECTION AND PREPARATIONFull-thickness sections of articular cartilage from tibial plateaus of operated
dogs were removed from the lesional (ﬁbrillated) and non-lesional (non-ﬁbril-
lated) areas as previously described27. Specimens from normal dogs ob-
tained from the same anatomical sites presented no macroscopic or
microscopic lesions. Cartilage specimens were ﬁxed in TissuFix #2 (Chaptec,
Montreal, QC, Canada), embedded in parafﬁn, and 5 mm sections prepared.IMMUNOHISTOCHEMISTRYThe specimens were processed as previously described27. The primary
antibodies were a mouse monoclonal anti-human follistatin (50 mg/ml; R&D
Systems, Minneapolis, MN, USA), a goat polyclonal anti-human gremlin
(4 mg/ml; Santa Cruz, Santa Cruz, CA, USA), a rabbit polyclonal anti-human
BMP-2/4 (4 mg/ml; Santa Cruz), a rabbit antiserum against IL-1b (2.1 mg/ml;
Rockland, Gilbertsville, PA, USA), and a rabbit polyclonal anti-bFGF (1/400
dilution; Chemicon, Temecula, CA, USA). Preliminary experiments showed
that each of the antibodies recognized the speciﬁc proteins.
Staining speciﬁcity was determined by: (1) immunoadsorption for 1 h at
37C with the corresponding protein or peptide: 20 molar excess recombi-
nant follistatin (R&D Systems), gremlin immunizing peptide (Santa Cruz),
BMP-2/4 peptide (Santa Cruz), recombinant IL-1b protein (R&D Systems),
recombinant bFGF (R&D Systems); (2) omission of the primary antibody;(3) substitution of the primary antibody with an autologous pre-immune se-
rum. These controls showed only background staining. Each section was ex-
amined under a light microscope (Leitz Diaplan; Wild Leitz, St. Laurent, QC,
Canada) and photographed with a Retiga OEM Fast camera (QImaging, Sur-
rey, BC, Canada).MORPHOMETRIC ANALYSISAntigen levels were quantiﬁed as previously described4 by determining
the number of chondrocytes that stained positive. The total number of cells
and the number of cells that stained positive for the speciﬁc antigen were ﬁrst
counted for the whole cartilage and then separately for each zone of the car-
tilage, at 40 magniﬁcation. Each slide was examined from 3 ﬁelds of the
superﬁcial (superﬁcial and upper intermediate layers) and 3 ﬁelds of the
deep (lower intermediate and deep layers) zones. The results were ex-
pressed as the percentage of cells that stained positive for the antigen, the
maximum being 100%. Each slide was subjected to a double-blind evalua-
tion; the ﬁnal score was determined by consensus of the 2 readers.CELL CULTUREChondrocytes were released from full-thickness strips of whole normal
dog cartilage by sequential enzymatic digestion at 37C28. The cells were
seeded at high density (105/cm2) and cultured in Dulbecco’s modiﬁed
Eagle’s medium (DMEM; Gibco BRL, Burlington, ON, Canada) supple-
mented with 10% heat-inactivated fetal calf serum (FCS; Gibco BRL) and
an antibiotic mixture (100 units/ml penicillin base and 100 mg/ml streptomycin
base; Gibco BRL) at 37C in a humidiﬁed atmosphere of 5% CO2/95% air.
The effects of growth factors on gremlin expression were assessed by
pre-incubating ﬁrst-passage cultured chondrocytes in DMEM/0.5% FCS for
24 h followed by another 24 h incubation with fresh DMEM/0.5% FCS con-
taining bFGF (100 ng/ml; R&D Systems), GDF-9 (100 ng/ml; Peprotech
Inc., Rocky Hill, NJ, USA) or BMP-2 (100 ng/ml; R&D Systems). Total ribo-
nucleic acid (RNA) was extracted and processed for real-time polymerase
chain reaction (PCR).RNA EXTRACTION AND REAL-TIME PCRTotal RNA was extracted and quantiﬁed4. Reverse transcription was
primed with random hexamers. Real-time PCR was performed as previously
described4 in the Rotor-Gene RG-3000A (Corbett Research, Mortlake,
Australia) with the SYBR GreenER PCR Master Mix (Invitrogen, Carlsbad,
CA, USA) used according to the manufacturer’s speciﬁcations. The 18S
was used as the housekeeping gene. The data were given as a threshold
cycle (Ct). Fold changes in gene expression were calculated as 2
DðDCtÞ,
where DCt¼Ct stimulatedCt18S, and D(DCt)¼DCt stimulatedDCt control.
The primer efﬁciencies for the genes were the same as those for the 18S
gene. The dog-speciﬁc primer sequences were 50-GAATCAGGGTT
CGATTCCG (sense), 50-CCAAGATCCAACTACGAGC (antisense) for 18S
and 50-ATGTGACCGAGCGCAAGTAC (sense), 50-ATATGCATCGACA
CTGCTTG (antisense) for gremlin.STATISTICAL ANALYSISData are expressed as the mean S.E.M. Statistical signiﬁcance was as-
sessed by 2-tailed Student’s t test, and P values< 0.05 were considered
signiﬁcant.ResultsMORPHOLOGICAL CHANGESThe monitoring of speciﬁc factors during the OA process
was done with cartilage obtained from non-operated (nor-
mal) or operated dogs sacriﬁced at 4, 8, 10 and 12 weeks
post-surgery. Specimens were taken from the non-lesional
(non-ﬁbrillated) and lesional (ﬁbrillated) areas to localize
the temporal and spatial production of the factors. Cartilage
histology of the normal dogs (Fig. 1) showed normal struc-
ture, cellularity, and matrix staining. OA changes over time
were similar to those described previously24,26,29: few le-
sions were detected at 4 weeks post-surgery, more lesions
appeared between the 4th and 8th weeks and progressed
over time, being most severe at 10 and 12 weeks. OA
Normal
Superficial zone
Deep zone
OA (8 weeks)
Non-Fibrillated Fibrillated
Superficial zone
Deep zone
Fig. 1. Representative histological sections of dog tibial plateaus from normal (non-operated) and OA cartilage 8 weeks post-surgery from non-
ﬁbrillated and ﬁbrillated areas. Cartilage from normal dogs shows normal structure, cellularity, and matrix staining. The non-ﬁbrillated area of
the OA cartilage presents surface irregularity (dotted arrows), hypercellularity and cloning (arrows) and slight discoloration of the matrix at the
superﬁcial zone. The ﬁbrillated area of the OA cartilage is characterized by ﬁbrillation (arrowheads), hypocellularity, and matrix discoloration
extending to the lower layers, as well as loss of matrix integrity and cartilage thickness. Magniﬁcation: 100.
265Osteoarthritis and Cartilage Vol. 17, No. 2non-lesional areas showed surface irregularities, hypercel-
lularity and cloning, and slight discoloration of the matrix
at the superﬁcial layer. The lesional areas showed ﬁbrilla-
tions, hypocellularity and matrix discoloration at the superﬁ-
cial and intermediate layers, reﬂecting loss of matrix
integrity and cartilage thickness.IMMUNOHISTOMORPHOMETRIC ANALYSISImmunohistomorphometry was chosen to determine the
relative amounts of follistatin, gremlin, BMP-2/4 and IL-1b
over time during OA progression and their locations in the
cartilage.
There was a time-dependent increase of follistatin pro-
duction in the non-ﬁbrillated OA cartilage (Fig. 2). This is
in contrast to the ﬁbrillated areas, where follistatin levels
were already high at week 4 and remained relatively stable
over time.
Gremlin levels (Fig. 2) were already statistically higher at
4 weeks in both the non-ﬁbrillated (P< 0.008) and ﬁbrillated
(P< 0.0001) areas compared to the normal cartilage.
Levels in the non-ﬁbrillated and ﬁbrillated areas of OA car-
tilage only slightly increased over time. Furthermore, grem-
lin levels were not signiﬁcantly different in the non-ﬁbrillated
and ﬁbrillated areas for each given week.
BMP-2/4 levels (Fig. 2) were high in the normal dogs, and
slightly increased over time in the non-ﬁbrillated cartilage to
reach statistical signiﬁcance at 10 and 12 weeks post-sur-
gery. Levels in the ﬁbrillated cartilage at 4 weeks post-sur-
gery were signiﬁcantly higher than in the normal and non-
ﬁbrillated cartilage for the same week and remained stable
over time.
The IL-1b production proﬁle followed a pattern similar to
that of follistatin (Fig. 2); a signiﬁcant increase occurred
over time in the non-ﬁbrillated cartilage, while levels at
week 4 in the ﬁbrillated cartilage were signiﬁcantly higher(P< 0.02) than in the normal cartilage and only slightly in-
creased over time.
The spatial production was monitored by evaluating pro-
tein levels in the superﬁcial (superﬁcial and upper interme-
diate layers) and deep (lower intermediate and deep layers)
zones of the cartilage. As illustrated in Figs. 3 and 4, differ-
ences were found in the distribution of the antagonists be-
tween the superﬁcial and deep zones.
Superficial zone (Fig. 3)
Each factor studied was present in the superﬁcial zones
of the normal dogs, but at different levels: follistatin and
gremlin at low levels of about 4%, IL-1b and BMP-2/4 at
13% and 22%, respectively. There was a progressive pro-
duction of follistatin over time in the non-ﬁbrillated areas
of OA cartilage that reached statistical difference from
week 8. In contrast, follistatin levels in the ﬁbrillated areas
were already signiﬁcantly higher at week 4 compared to
the normal (P< 0.001) and the non-ﬁbrillated areas at 12
weeks (P< 0.02). The levels in the ﬁbrillated areas did
not vary from 4 to 10 weeks (21e24%), and a slight de-
crease was found at 12 weeks.
Gremlin levels were signiﬁcantly higher at 4 weeks in
the non-ﬁbrillated areas (P< 0.03) and the levels slightly
increased with disease progression, but not signiﬁcantly
compared to week 4. In the ﬁbrillated areas, levels
were already statistically higher at 4 weeks (P< 0.001)
and remained elevated and stable until the end of the
study at week 12.
BMP-2/4 levels were relatively high in the normal carti-
lage, and did not vary signiﬁcantly in the OA non-ﬁbrillated
cartilage, although a small increase was found at 10 and 12
weeks. The levels at these times were similar to those seen
at 4 weeks in the ﬁbrillated areas. A small but signiﬁcant in-
crease was noted at week 10 in the ﬁbrillated areas.
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Fig. 2. Temporal production levels of follistatin, gremlin, BMP-2/4, and IL-1b in the full thickness of cartilage from normal and operated dogs at
4, 8, 10 and 12 weeks in non-ﬁbrillated (NF) and ﬁbrillated (F) areas. Protein production was determined by immunomorphometric analysis as
described in Materials and methods. P values were calculated by 2-tailed Student’s t test.
266 G. Tardif et al.: BMP antagonists in early osteoarthritisIL-1b levels increased over time in the non-ﬁbrillated
areas of the cartilage; statistical signiﬁcance was reached
for weeks 8e12 compared to the normal cartilage. Levels
decreased slightly at week 12, suggesting attenuation in
the inﬂammatory process. IL-1b levels in the ﬁbrillated
areas were signiﬁcantly higher at week 4 (P< 0.02), re-
mained relatively constant at weeks 8 and 10, and as
seen in the non-ﬁbrillated cartilage, decreased slightly at
week 12.
In summary, follistatin and IL-1b levels in the superﬁcial
zone showed similar proﬁles in both ﬁbrillated and non-
ﬁbrillated areas; gremlin and BMP-2/4 also showed similar
proﬁles, the only difference being a high BMP-2/4 level in
the normal cartilage.
Deep zone (Fig. 4)
The levels of the factors studied were lower in the deep
(Fig. 4) than in the superﬁcial zones (Fig. 3). There were
very few cells showing immunoreactivity toward follistatin
in the deep zone for both non-ﬁbrillated and ﬁbrillated areas.
Slightly higher levels were found in the ﬁbrillated areas com-
pared to the non-ﬁbrillated, which reached signiﬁcance only
after week 8. Gremlin production in the superﬁcial zone in-
creased with disease progression in both the non-ﬁbrillated
and ﬁbrillated areas.
BMP-2/4 production in the deep zone differed from that
seen in the superﬁcial zones: normal cartilage levels were
lower (6%), production increased over time in the non-ﬁbril-
lated areas from week 4 (12%) to week 12 (26%), and
levels were already signiﬁcantly higher in the ﬁbrillatedareas at week 4 (P< 0.0007). These levels decreased at
8e10 weeks but reverted at 12 weeks. Of note, these
values were not signiﬁcantly different within the weeks. IL-
1b levels were low in the deep layers of normal cartilage
(3%) and increased in a time-dependent fashion in both
non-ﬁbrillated and ﬁbrillated areas. Levels were maximal
at week 10, and as in the superﬁcial zone, decreased
slightly at week 12 in the non-ﬁbrillated areas.
In summary, gremlin and BMP-2/4 levels in the deep
zone followed a similar production pattern especially in
the non-ﬁbrillated areas, IL-1b increased with disease pro-
gression, and follistatin levels remained very low.FACTORS INVOLVED IN THE UP-REGULATION OF GREMLINOur previous studies have shown that BMP-2/4 was the
only factor tested that could up-regulate gremlin expres-
sion in human chondrocytes4. However, in the normal
dog cartilage, the high levels of BMP-2/4 contrasted with
the low levels of gremlin and its statistical up-regulation
early during the disease process. In order to identify which
factor could have contributed to the increased gremlin pro-
duction in the OA cartilage, we determined the effects of
some factors either related to the OA process or known
up-regulators of gremlin expression, BMP-2, bFGF and
GDF-9.
Chondrocytes (n¼ 5) were treated for 24 h with these
factors and the expression level of gremlin was determined
by real-time PCR. The results showed that GDF-9 did not
signiﬁcantly affect gremlin expression but that BMP-2 and
bFGF markedly induced gremlin expression by 1.6 0.1
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Fig. 3. Temporal production levels of follistatin, gremlin, BMP-2/4, and IL-1b in the superﬁcial zone of cartilage from normal and operated dogs
at 4, 8, 10 and 12 weeks in non-ﬁbrillated (NF) and ﬁbrillated (F) areas. Protein production was determined by immunomorphometric analysis
as described in Materials and methods. P values were calculated by 2-tailed Student’s t test.
267Osteoarthritis and Cartilage Vol. 17, No. 2fold (P< 0.0001) and 3.2 0.9 fold (P< 0.03), respectively.
Hence, we looked for bFGF production in normal and OA
dog cartilage (8 weeks) to verify whether the presence of
this factor could correlate with the up-regulation of gremlin
production with time. Results showed (Fig. 5) that although
similar levels of bFGF (20e22%) were produced in both
normal and OA cartilage and positive-staining cells were
mainly localized in the superﬁcial zones of both, a very
important difference was the presence of marked positive
staining throughout the extracellular matrix in the OA
cartilage only.Discussion
Animal models of OA allow evaluation of temporal and
spatial changes occurring in joint tissues during the pro-
gression of the disease. Although no animal model will rep-
resent exactly the events leading to human OA, they
provide a good basis for understanding the role of speciﬁc
molecules in the evolution of the disease. We chose the
ACL dog model as it mimics changes seen in human OA
at the molecular level but also because pro-inﬂammatory
factors play a role in bringing about the structural changes,
as they do in human OA. As our study aimed at investigat-
ing the production of factors in cartilage in a temporal and
spatial manner, immunohistochemisty/morphometric analy-
sis was used as it provides data not only on the relative
abundance of a protein, but also its speciﬁc location
throughout the evolution of the disease.
While the etiology of articular cartilage degeneration seen
in OA is not fully understood, cytokines and growth factorsplay critical mediatory roles. Indeed, it is hypothesized that
during the course of the disease insufﬁcient or poor quality
of new matrix macromolecules occurs as a consequence of
deﬁcient stimulation. Since growth factors of the BMP family
are important regulators of matrix production, decreased ac-
tivity of these factors through increased production of BMP
antagonists could lead to the development of an altered ma-
trix. We and others have shown that BMP antagonists are
produced in adult cartilage, and that some are found at
higher levels in human OA cartilage3e5. We have also
shown that in human OA cartilage, follistatin and gremlin
are produced in different areas3,4: follistatin is found
primarily in the superﬁcial layers of cartilage, while gremlin
is mostly detected in the upper intermediate layers. As
follistatin is up-regulated by the inﬂammatory molecules
tumor necrosis factor (TNF)-a and interferon (IFN)-g4, we
hypothesized that this antagonist would be linked particu-
larly to the inﬂammatory process of the disease, while
gremlin, because of its up-regulation by BMPs, would be
associated preferentially with the remodeling phase.
Results from this study conﬁrm that the production of both
follistatin and gremlin is up-regulated during OA, and that
follistatin is located mostly in the superﬁcial zone of the car-
tilage while gremlin is produced in both the superﬁcial and
deeper layers. These data, in addition to the signiﬁcant
up-regulation of gremlin at 4 weeks post-surgery, earlier
than follistatin, conﬁrm our hypothesis that gremlin is in-
volved during the early phases.
The very early stage of OA has been characterized by
a hypertrophic biochemical repair reaction and increased
synthesis of extracellular matrix. BMP-2 and -4 are growth
factors that are expressed at this stage. Nakase et al.6
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Fig. 4. Temporal production levels of follistatin, gremlin, BMP-2/4, and IL-1b in the deep zone of cartilage from normal and operated dogs at 4,
8, 10 and 12 weeks in non-ﬁbrillated (NF) and ﬁbrillated (F) areas. Protein production was determined by immunomorphometric analysis as
described in Materials and methods. P values were calculated by 2-tailed Student’s t test.
268 G. Tardif et al.: BMP antagonists in early osteoarthritishave reported that BMP-2 is scarce in normal adult human
cartilage, is found in moderately damaged OA cartilage in
the upper and middle layers, and in severely damaged car-
tilage extends to the deep layers. Interestingly, our previous
work showed a similar production pattern for gremlin in hu-
man OA cartilage4. In this study, similar expression patterns
of gremlin and BMP-2/4 were also observed: they are pro-
duced in both superﬁcial and deep cartilage zones, in con-
trast to follistatin which is produced mainly in the superﬁcial
zone, strongly suggesting that BMP-2/4 and gremlin, ratherFig. 5. Representative sections of bFGF immunostaining from normal and
drocytes from both normal and OA cartilage, mainly at the superﬁcial zone
only in the OA cartilage throughout the cathan follistatin, are associated with the remodeling phase of
the cartilage matrix.
Moreover, the fact that follistatin is involved later during
the OA process as well as its similar topographical distribu-
tion with IL-1b at the superﬁcial zone, suggests that the two
molecules may be regulated by similar pro-inﬂammatory
stimuli, strongly supporting a link between follistatin produc-
tion and the inﬂammatory process of this disease. Also
supportive of this link is that follistatin preferentially binds
activin, a molecule expressed during some inﬂammatoryOA dog cartilage 8 weeks post-surgery. bFGF was found in chon-
. However, diffuse staining in the extracellular matrix was observed
rtilage layers. Magniﬁcation: 100.
269Osteoarthritis and Cartilage Vol. 17, No. 2arthropathies30, over BMPs. Of note, and according to our
previous work with human OA chondrocytes4, IL-1b is not
the likely factor responsible for the increased follistatin pro-
duction, but was used in this study as it is indicative of the
inﬂammatory process occurring in this tissue.
One unexpected ﬁnding was that the BMP-2/4 levels
were relatively high in the normal dog cartilage and were
not up-regulated in the superﬁcial zone of the cartilage,
whereas gremlin levels were low in the normal cartilage
and signiﬁcantly increased at 4 weeks in both non-ﬁbrillated
and ﬁbrillated areas. These data suggest that factors other
than BMP-2/4 are able to stimulate gremlin in dog OA car-
tilage. We looked for factors that might trigger the up-regu-
lation of gremlin in dog chondrocytes. GDF-9 has been
shown to increase gremlin expression in mouse granulosa
cells31, but our data showed that this factor does not signif-
icantly alter gremlin expression in dog chondrocytes. In con-
trast, bFGF as well as BMP-2 markedly up-regulated
gremlin expression in dog chondrocytes; furthermore,
bFGF was found at an increased level in the OA cartilage
matrix. Although bFGF is one of many factors present in
OA cartilage, it may modulate gremlin expression in vivo
as it is produced by the chondrocytes, stored in the extra-
cellular matrix and is released from the matrix upon carti-
lage damage/injury. In addition, bFGF was suggested to
contribute to the progression of OA as it interferes with
the anabolic activities of insulin-like growth factor (IGF)-1
and BMP-7 in chondrocytes32 and stimulates matrix metal-
loprotease (MMP)-13 expression33, a metalloprotease ca-
pable of degrading many components of the extracellular
matrix28,34e36. Our data show that bFGF is present in chon-
drocytes as well as in the OA cartilage matrix throughout
the cartilage layers. The release of this growth factor may
then contribute to the up-regulation of gremlin seen in OA
dog cartilage.
In our previous study of gremlin regulation in OA human
chondrocytes4, we found that among all the cytokines and
growth factors tested, only BMP-2 and -4 increased gremlin
while IL-1b decreased its expression. Data from this study
are in agreement with this observation, as they show an in-
verse correlation between gremlin and IL-1b production:
gremlin production in the whole cartilage decreases at 10
weeks, which is also the time when IL-1b increases, and
its production is again increased at 12 weeks, when IL-1b
is decreased.
IL-1b has been reported to increase BMP-2/4 expression
in normal and OA human chondrocytes37. This cytokine may
also be a regulating factor for BMP-2/4 levels in the dog
model. Indeed, although IL-1b basal levels were relatively
high in the whole cartilage, production slowly increased
with disease progression in the non-ﬁbrillated areas and
was already signiﬁcantly higher at week 4 in the ﬁbrillated
areas. This pattern was somewhat similar for BMP-2/4.
However, although BMP-2/4 levels increased over time,
this was accompanied by increased levels of gremlin and fol-
listatin, thus reducing the anabolic activities of the BMPs.
The up-regulation of gremlin and follistatin in OA cartilage
is likely the consequence of the actions of different factors,
resulting in differential production at different stages of the
disease. Gremlin is associated with the remodeling/early
phase and follistatin with the inﬂammatory process. This
suggests the possibility that these proteins have functions
other than being extracellular BMP antagonists in the OA
process. Indeed, different functions were recently discov-
ered for gremlin. In relation to the BMP system, gremlin
was recently found to interact with the intracellular BMP-4
precursor and prevent the secretion of mature BMP-438. Italso binds factors other than BMPs, such as the polypeptide
YWHAH (tyrosine 3-monooxygenase/tryptophan 5-mono-
oxygenase activation protein eta polypeptide)39, a protein
that mediates signal transduction by binding to phosphoser-
ine-containing proteins, and the Slit proteins, molecules in-
volved in the regulation of monocyte chemotaxis40. In
addition, gremlin was shown to activate the transcription
of p21Cip141, involved in the cell cycle. Finally, gremlin
was also reported to be a proangiogenic factor42. Although
these factors have not yet been related to the OA process, it
will be interesting to investigate whether gremlin’s other ac-
tivities/properties might be involved in the physiological or
pathological cartilage processes.
In summary, despite the constant presence of BMPs in
OA cartilage, these molecules might not be optimally active
due to the increased levels of speciﬁc antagonists resulting
in decreased production of matrix macromolecules such as
collagen and proteoglycan, and a shift toward degradation
rather than matrix synthesis and repair. The potential inter-
ference with BMP activity of different BMP antagonists dur-
ing OA progression should be taken into consideration in
the design of cartilage repair therapies involving BMPs.Conﬂict of interest
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